1. Introduction {#sec1-diagnostics-10-00120}
===============

Ovarian cancer is the most lethal gynecological malignancy since most cases are diagnosed at an advanced stage when the metastases are extensive. In an effort to detect ovarian cancer at an early stage when the disease has a more favorable prognosis, ovarian cancer screening has been performed for more than three decades \[[@B1-diagnostics-10-00120],[@B2-diagnostics-10-00120]\]. However, unfortunately, current methods for ovarian cancer screening, i.e., transvaginal ultrasonography (TV-US) and serum cancer antigen (CA)-125 measurements, did not reduce the mortality rate \[[@B3-diagnostics-10-00120],[@B4-diagnostics-10-00120],[@B5-diagnostics-10-00120]\]. Hence, routine screening of the general population for ovarian cancer is not recommended at present \[[@B6-diagnostics-10-00120]\].

Recently our understanding of the origins and pathogenesis of ovarian cancer has substantially progressed, and novel methods for early detection of ovarian cancer have been developed. Although the etiology of ovarian cancer remains unclear, some novel hypotheses have been proposed to explain epidemiological risk factors. In this review, we discuss current and novel screening methods for ovarian cancer, in particular, high-grade serous carcinoma (HGSC), based on its carcinogenesis. Additionally, we propose a hypothesis of its etiology, incessant retrograde bleeding, and address primary prevention for HGSC.

2. Ovarian Cancer Screening: Current Methods and Limitations {#sec2-diagnostics-10-00120}
============================================================

In the general population, ovarian cancer screening using TV-US and serum CA-125 measurements has detected many early-stage cancers. However, three randomized trials using these methods did not detect the disease at an early stage or achieve a mortality reduction in asymptomatic postmenopausal women \[[@B3-diagnostics-10-00120],[@B4-diagnostics-10-00120],[@B7-diagnostics-10-00120]\]. Kobayashi et al. investigated the efficacy of screening with sequential pelvic ultrasound and serum CA-125 test in 82,467 postmenopausal women in Japan and reported that the proportion of stage I ovarian cancer was higher in the screened group than in the control group (63% vs. 38%), but the difference was not statistically significant (*p* = 0.229) \[[@B7-diagnostics-10-00120]\]. Buys et al. investigated 78,216 women aged 55 to 74 years in the United States and concluded that among women in the general population, simultaneous screening with CA-125 and TV-US did not reduce ovarian cancer mortality compared with usual care. They also reported that a false-positive screening test result led to complications with unnecessary surgery \[[@B3-diagnostics-10-00120]\]. Jacobs et al. investigated 202,638 postmenopausal women aged 50 to 74 years in the United Kingdom and reported that the mortality reduction was not significant, whereas a significant mortality reduction with multimodal screening was observed when prevalent cases (diagnosed at the first screen visit) were excluded \[[@B4-diagnostics-10-00120]\].

The prevalence of ovarian cancer in the general population is relatively low (1:2500) \[[@B8-diagnostics-10-00120]\], and higher prevalence was observed in women considered to be at high risk. High-risk women have cancer predisposing gene mutations (lifetime risk, 10--40%), i.e., those with *BRCA1/BRCA2* mutations or those with Lynch syndrome. Women at low-risk (lifetime risk, 1--2%) have no family history of ovarian cancer or a single first-degree relative with ovarian cancer, and women at moderate-risk (lifetime risk, 3--10%) have a more significant history but no mutations in *BRCA* genes \[[@B9-diagnostics-10-00120]\]. However, even in women with a *BRCA1/2* mutation, who are actually at high risk of developing ovarian cancer among women with family history \[[@B10-diagnostics-10-00120]\], ovarian cancer screening using TV-US and CA-125 measurements did not detect ovarian cancer at an early stage \[[@B11-diagnostics-10-00120],[@B12-diagnostics-10-00120]\].

Although the sensitivity of ovarian cancer screening using TV-US in a study was 87% \[[@B13-diagnostics-10-00120]\], which outperformed screening mammography \[[@B14-diagnostics-10-00120]\], the limitations of screening using current methods can be partly explained by its limitations in detecting HGSC, which is the most common and lethal subtype of ovarian cancer.

3. Pathogenesis of High-Grade Serous Carcinoma: Fallopian Tube- and Ovarian-Derived Tumors {#sec3-diagnostics-10-00120}
==========================================================================================

3.1. Ovarian Carcinoma, a Group of Distinct Diseases {#sec3dot1-diagnostics-10-00120}
----------------------------------------------------

Epithelial ovarian cancer is not a single disease, but a heterogeneous group of neoplasms that are classified into five main cell types: high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous carcinomas. These five subtypes are essentially distinct tumors because they not only behave differently but also develop differently \[[@B15-diagnostics-10-00120],[@B16-diagnostics-10-00120],[@B17-diagnostics-10-00120]\]. Additionally, ovarian cancers can be divided into type I and II tumors \[[@B16-diagnostics-10-00120]\]. Type I tumors include low-grade serous, endometrioid, clear cell, and mucinous carcinomas. Type II tumors include high-grade serous and endometrioid carcinomas. Type I tumors are suggested to develop from benign extraovarian lesions that implant on the ovary and that can subsequently undergo malignant transformation \[[@B16-diagnostics-10-00120],[@B17-diagnostics-10-00120]\]. Thus, they are thought to arise from precursor lesions that develop in the ovary. Endometrioid and clear cell carcinomas appear to develop in ovarian endometriotic cysts and low-grade serous carcinomas appear to develop from borderline tumors \[[@B16-diagnostics-10-00120],[@B17-diagnostics-10-00120]\]. Mucinous carcinoma is a rare subtype and its carcinogenesis is still unknown. Most type I tumors can be detected early by TV-US with or without CA-125 measurements \[[@B18-diagnostics-10-00120]\]. In contrast, many type II carcinomas develop from intraepithelial carcinomas in the fallopian tube \[[@B16-diagnostics-10-00120],[@B17-diagnostics-10-00120],[@B19-diagnostics-10-00120]\].

3.2. High-Grade Serous Carcinogenesis {#sec3dot2-diagnostics-10-00120}
-------------------------------------

Recent studies, in particular, studies on risk-reducing salpingo-oophorectomy (RRSO) performed in women with a *BRCA* mutation, have revealed that many HGSCs, i.e., the most common type II tumor, arise in the fallopian tube, particularly in the fimbriae \[[@B16-diagnostics-10-00120],[@B19-diagnostics-10-00120]\]. A large majority of sporadic cases of HGSCs also arise in the fallopian tube \[[@B20-diagnostics-10-00120]\]. *TP53* mutation is observed in almost all HGSC cells \[[@B21-diagnostics-10-00120],[@B22-diagnostics-10-00120]\] and appears to be a driver mutation in the pathogenesis of HGSC \[[@B22-diagnostics-10-00120]\]. In animal models, deletions of *Brca*, *Tp53*, and *Pten* lead to the development of HGSCs arising from fallopian tube secretory cells \[[@B23-diagnostics-10-00120]\], and inactivation of several tumor suppressor genes, including *Brca* and *Trp53*, results in serous tubal intraepithelial carcinomas (STICs) \[[@B24-diagnostics-10-00120]\].

In the fallopian tube surface epithelium, intraepithelial lesions associated with HGSC, i.e., p53 signature, serous tubal intraepithelial lesion (STIL), and STIC can be identified. p53 signature is characterized by a linear, strongly immunopositive segment of tubal cells spanning at least 12 consecutive secretory cell nuclei, and no cytological atypia and very low proliferative index. STILs are intermediate lesions between p53 signature and STIC, representing no cytological atypia, low/moderate proliferative index, but p53 accumulation. STICs are composed of secretory cells showing significant atypia, architectural alterations, high proliferative index, and strong p53 immunostaining \[[@B25-diagnostics-10-00120]\].

p53 signature may not necessarily be associated with the development of HGSC. p53 signature was observed in 50% of women without a *BRCA* mutation who underwent a salpingectomy for benign diseases \[[@B26-diagnostics-10-00120]\]. In contrast, STIC may be a putative precursor of HGSC \[[@B27-diagnostics-10-00120]\]. STIC was observed only in 0.1--0.8% of low-risk women, such as women without a history of or known risk factors (*BRCA* mutation) for HGSC \[[@B28-diagnostics-10-00120],[@B29-diagnostics-10-00120]\]. Another study reported that the incidence of STIC in women without *BRCA* mutation was much higher, 3%; in that study 8% of women with *BRCA* mutation had a STIC \[[@B30-diagnostics-10-00120]\]. STIC has malignant cellular features, such as enlarged nuclei and prominent nucleoli, which are also characteristic histopathological features of HGSC. In a population-based study, although HGSC incidence rates were relatively stable, those of fallopian tube carcinoma in situ (an imperfect surrogate of STIC) increased recently, which appears to reflect increased detection with meticulous pathology processing protocols \[[@B31-diagnostics-10-00120]\]. The existence of occult tubal carcinoma in situ may not affect long-term survival, as five-year cause-specific survival was 98%.

Ovarian surface epithelium (OSE) is also a cell of origin for HGSC. Many ovarian HGSCs, particularly advanced-stage disease, do not have STICs. The reported coexistence between STICs and HGSCs ranged from 11% to 61% (mean 31%) \[[@B32-diagnostics-10-00120]\]. A genomic study reveals that a proportion of STICs represents intraepithelial metastases to the fallopian tube rather than the origin of HGSC \[[@B33-diagnostics-10-00120]\]. In a mouse model, ovaries harboring a *p53* mutation develop metastatic HGSCs \[[@B34-diagnostics-10-00120]\], and transcriptome data from OSE, fallopian tube epithelium (FTE), and HGSC samples reveal that HGSC has two subtypes originated from either FTE or OSE \[[@B35-diagnostics-10-00120]\]. Interestingly, OSE-derived HGSC may have a worse prognosis and long latent period compared to FTE-derived HGSC \[[@B36-diagnostics-10-00120],[@B37-diagnostics-10-00120]\].

In *BRCA* mutation carriers that underwent RRSO, the majority of microscopic cancers were observed in the fallopian tubes. In addition, microscopic cancers were observed only in the ovary or peritoneal washings in some women \[[@B38-diagnostics-10-00120]\]. These observations may be explained by the phenomenon called "early precursor escape" \[[@B39-diagnostics-10-00120]\]. Early serous proliferations, i.e., p53 signature and STILs, which lack cellular atypia but contain *TP53* mutations, can be shed from the fallopian tube and eventually undergo malignant transformation on the ovarian or peritoneal surface, as well as STICs.

4. Screening Methods for High-Grade Serous Carcinoma {#sec4-diagnostics-10-00120}
====================================================

The main goal of screening for a particular cancer is to reduce the mortality rate from that cancer among the persons screened. Hence, the detection of preinvasive lesions, or at least small curable lesions, is required for cancer screening.

4.1. Conventional Screening Methods {#sec4dot1-diagnostics-10-00120}
-----------------------------------

For early detection of ovarian cancer before the development of overt symptoms, imaging studies, such as ultrasonography, are useful ([Table 1](#diagnostics-10-00120-t001){ref-type="table"}). Imaging studies can detect a lesion approximately \>1 cm in diameter; hence, they may not be effective in HGSC screening, because cancer cells can exfoliate from the original lesion before it grows to a mass detectable by imaging studies. However, in asymptomatic women 50 years of age or older or women 25 years of age or older with a family history of ovarian cancer, women with type II ovarian tumors (the vast majority were HGSCs) that were detected by screening using ultrasonography had a significantly longer disease-specific survival than women with clinically detected type II tumors \[[@B13-diagnostics-10-00120]\]. Thus, a certain number of ovarian HGSCs develop an ovarian tumor that can be detected with ultrasonography before they develop extensive metastases.

Serum CA-125 is the most sensitive tumor marker for ovarian cancer, whereas many serum biomarkers have been developed \[[@B40-diagnostics-10-00120]\]. CA-125 is useful for the detection of a low-volume disease; however, in a mathematical model, ovarian cancer can reach a volume of π/6(25 mm)^3^ , corresponding to a spherical diameter of about 25 mm, before becoming detectable by current clinical blood assays \[[@B41-diagnostics-10-00120]\].

4.2. Novel Screening Methods Based on Carcinogenesis {#sec4dot2-diagnostics-10-00120}
----------------------------------------------------

Many novel approaches have been investigated to overcome the limitations inherent to current screening methods, i.e., TV-US and CA-125 measurements. Blood testing may be beneficial to detect a smaller lesion. As a tumor grows, tumor cells invade into capillaries, and then tumor DNA and proteins are released from apoptotic and necrotic tumor cells into the bloodstream. Thus, circulating tumor DNA (ctDNA) and proteins can be detected in the blood, as well as autoantibodies to tumor DNA \[[@B42-diagnostics-10-00120],[@B43-diagnostics-10-00120],[@B44-diagnostics-10-00120],[@B45-diagnostics-10-00120],[@B46-diagnostics-10-00120]\]. However, these biomarkers appear to be detected only after an invasive tumor becomes a certain size, as a load of circulating tumor DNA correlates with tumor staging \[[@B47-diagnostics-10-00120]\].

Recent progress in cancer detection methods may allow the detection of precursor lesions of HGSC ([Table 1](#diagnostics-10-00120-t001){ref-type="table"}). At a stage of an intraepithelial tumor, HGSC may be detected from materials other than blood. As carcinoma cells shed from the distal fallopian tube can flow into the endometrial cavity, endometrial cytological testing can detect these cells \[[@B48-diagnostics-10-00120],[@B49-diagnostics-10-00120]\]. For endometrial cytological evaluation, samples are obtained from the endometrial cavity using a disposable plastic brush (endometrial sampler). The samples obtained are usually smeared directly on slides for fixation and staining. Cervicovaginal cytology can also detect carcinoma cells. We performed a review of the literature regarding ovarian and fallopian tube cancer detected by the endometrial and cervicovaginal cytological testing. References for this review were identified through searches of PubMed (for papers published in English) and Igaku Chuo Zasshi (Medical Central Journal; for papers published in Japanese) with the search terms 'ovarian cancer', 'fallopian tube cancer', 'cervical smear (cytology)', and 'endometrial smear (cytology)' from 1985 until December, 2014. Articles were also identified through searches of the authors' own files. We only included cases in which there were no abnormalities on transvaginal ultrasonography, but fallopian tube or ovarian carcinomas were detected by examining cytological samples. Cases with cytological findings positive for malignant cells were included, but cases with atypical but not malignant cells were excluded. Additionally, patients in whom a presurgical serum CA-125 measurement was performed were included. The review revealed that these cytological tests can detect ovarian and fallopian tube carcinomas without abnormalities on imaging studies \[[@B49-diagnostics-10-00120],[@B50-diagnostics-10-00120],[@B51-diagnostics-10-00120],[@B52-diagnostics-10-00120],[@B53-diagnostics-10-00120],[@B54-diagnostics-10-00120],[@B55-diagnostics-10-00120],[@B56-diagnostics-10-00120],[@B57-diagnostics-10-00120],[@B58-diagnostics-10-00120],[@B59-diagnostics-10-00120],[@B60-diagnostics-10-00120],[@B61-diagnostics-10-00120],[@B62-diagnostics-10-00120],[@B63-diagnostics-10-00120],[@B64-diagnostics-10-00120],[@B65-diagnostics-10-00120],[@B66-diagnostics-10-00120],[@B67-diagnostics-10-00120],[@B68-diagnostics-10-00120]\] ([Table 2](#diagnostics-10-00120-t002){ref-type="table"}). Of note, in 17 of 23 cases (74%) serum CA-125 levels were not elevated.

Tumor DNA and tumor proteome can be detected from samples obtained from the endometrial cavity or cervix in women with endometrial and/or ovarian cancer \[[@B69-diagnostics-10-00120],[@B70-diagnostics-10-00120],[@B71-diagnostics-10-00120],[@B72-diagnostics-10-00120],[@B73-diagnostics-10-00120]\]. Although in these studies patients with invasive carcinoma (stages I-IV) were investigated, these biomarkers can theoretically detect precursor lesions such as STIC. Falloposcopy may be effective in collecting atypical cells of the fimbria \[[@B74-diagnostics-10-00120]\]. Biomarkers in the urine and exhaled breath samples may be useful in detecting preclinical cancer \[[@B75-diagnostics-10-00120],[@B76-diagnostics-10-00120]\].

Circulating microRNAs appear to be effective in the early detection of ovarian cancer \[[@B77-diagnostics-10-00120],[@B78-diagnostics-10-00120]\]. MicroRNA (miRNA) is a small (20--25 nucleotides), non-coding RNA that regulates gene expression post-transcriptionally, and stable in the blood. A panel using eight miRNAs effectively detected invasive ovarian cancer including early-stage disease \[[@B77-diagnostics-10-00120]\]. Additionally, the model could distinguish ovarian cancer patients from those with benign tumors.

Light-induced endogenous fluorescence can identify preinvasive lesions via falloposcopy \[[@B79-diagnostics-10-00120]\]. An implantable optical sensor, which is composed of an antibody-functionalized carbon nanotube complex and placed proximal to disease sites, can detect HE4 in the patient biofluids \[[@B80-diagnostics-10-00120]\].

For a screening test to be effective, it should be sensitive and specific, as well as cost-effective. In particular, a high positive predictive value is required to avoid unnecessary surgery which may cause morbidity. Among many novel screening methods that are now being investigated, only cytological testing appears to be available at present. This testing appears to have a high positive predictive value because STIC cells have severe nuclear atypia. Additionally, this testing method is inexpensive, well tolerated by patients, and easily performed by gynecologists in clinical settings \[[@B81-diagnostics-10-00120]\]. However, limitations of endometrial cytological testing include low sensitivity, which was found to be 43% or less for HGSC in our previous study \[[@B49-diagnostics-10-00120]\]. In women with cervical stenosis, which is observed more often in elderly women, this testing cannot be performed. Additionally, whether endometrial cytological testing can detect carcinomas early enough to improve outcome has yet to be determined. Based on our previous study \[[@B49-diagnostics-10-00120]\] and a review of the literature, we have been performing an ovarian cancer screening program consisting of TV-US, CA-125, and endometrial cytological tests in high-risk women who do not want to undergo RRSO. Other novel methods, such as molecular and endoscopic methods, are necessary to be clinically validated in a prospective cohort.

5. Incessant Retrograde Bleeding---An Etiologic Factor in High-Grade Serous Carcinogenesis {#sec5-diagnostics-10-00120}
==========================================================================================

Since current screening methods are not effective in reducing ovarian cancer mortality, primary prevention of ovarian cancers should be considered. To develop effective prevention methods, identification of risk factors is necessary.

5.1. Risk Factors of Ovarian Carcinoma and Carcinogenesis Hypotheses {#sec5dot1-diagnostics-10-00120}
--------------------------------------------------------------------

Epidemiological studies have shown that protective factors of ovarian carcinoma include oral contraceptive (OC) use, parity, and breastfeeding \[[@B82-diagnostics-10-00120],[@B83-diagnostics-10-00120]\]. These factors are associated with ovulation suppression; hence, the incessant ovulation hypothesis was postulated \[[@B84-diagnostics-10-00120]\]. Constant damage and repair of the OSE lead to an increased risk of malignant transformation \[[@B85-diagnostics-10-00120]\]. Ovulation-related inflammation may play a role in high-grade serous carcinogenesis: follicular fluid exposure causes up-regulation of inflammatory and DNA repair pathways and double-stranded DNA breaks are induced \[[@B86-diagnostics-10-00120]\]. However, this hypothesis does not explain why tubal ligation reduces ovarian cancer risk \[[@B87-diagnostics-10-00120]\], after which the incessant menstruation hypothesis has been postulated \[[@B88-diagnostics-10-00120]\]. Retrograde menstruation from the endometrial cavity into the Douglas pouch and subsequent iron-induced oxidative stress in bloody fluid are the causative mechanisms. Fimbriae floating in bloody peritoneal fluid are exposed to the action of catalytic iron and the genotoxic effect of reactive oxygen species \[[@B88-diagnostics-10-00120]\]. Transferrin-containing fluid, such as retrograde menstrual blood, may induce DNA double-strand breaks that potentially lead to DNA damage/genome instability \[[@B89-diagnostics-10-00120]\]. Whereas incessant menstruation hypothesis explains ovarian cancer risk well in the premenopausal period, another risk factor is associated with ovarian carcinogenesis in menopausal women.

5.2. Incessant Retrograde Bleeding Hypothesis {#sec5dot2-diagnostics-10-00120}
---------------------------------------------

Menopausal hormone therapy (MHT), also called hormone replacement therapy, increases ovarian cancer risk \[[@B90-diagnostics-10-00120],[@B91-diagnostics-10-00120],[@B92-diagnostics-10-00120]\]. Considering this effect, incessant retrograde bleeding, which is an expansion of the concept of incessant menstruation, may explain more accurately the etiology of HGSC in menopausal women. In menopausal women experiencing vasomotor symptoms, estrogen therapy represents the most effective treatment \[[@B93-diagnostics-10-00120]\], but progestin is also given to prevent endometrial cancer whereas breast cancer risk is increased with estrogen plus progestin \[[@B94-diagnostics-10-00120]\]. MHT regimens are classified into three types: estrogen alone, estrogen with sequentially added progestin (sequential E + P), and continuous estrogen and progestin (continuous E + P). The use of estrogen alone causes irregular endometrial bleeding (breakthrough bleeding) and sequential E + P causes regular endometrial bleeding (withdrawal bleeding). In contrast, continuous E + P usually causes atypical bleeding at first but results in endometrial atrophy with bleeding cessation \[[@B95-diagnostics-10-00120]\].

The risk of serous ovarian cancer differs by the regimen of MHT ([Table 3](#diagnostics-10-00120-t003){ref-type="table"}). Its risk in women with intact uteri is increased with the use of estrogen alone and sequential E + P \[[@B90-diagnostics-10-00120],[@B92-diagnostics-10-00120]\], but the use of continuous E + P does not change the risk \[[@B92-diagnostics-10-00120]\]. Thus, regimens that cause endometrial bleeding, which is usually associated with retrograde bleeding into the Douglas pouch, are associated with increased risk of serous ovarian carcinoma. In the past, women with intact uteri also received estrogen alone, but currently, only hysterectomized women are treated with this regimen. The risk of fallopian tube carcinomas, almost all of which are thought to be HGSC, was increased with the use of sequential E + P but did not change with the use of continuous E + P \[[@B91-diagnostics-10-00120]\]. Of note, estrogen alone did not change the risk of fallopian tube carcinoma in hysterectomized women \[[@B91-diagnostics-10-00120]\]. In contrast, estrogen alone increased the risk of serous ovarian carcinoma in hysterectomized women, particularly for five or more years of use \[[@B92-diagnostics-10-00120]\], although it does not cause retrograde bleeding. This discrepancy may be explained by the grade of serous carcinoma that develops after MHT use. Low-grade serous carcinoma develops from serous cystadenoma in the ovary, and ovarian serous cystadenoma is suggested to arise from epithelial inclusion glands that originate in the fallopian tube \[[@B96-diagnostics-10-00120]\]. As estrogen stimulates proliferation of the fallopian tube epithelial cells \[[@B97-diagnostics-10-00120]\], the majority of ovarian serous carcinoma that develops after long-term use of estrogen may be low-grade serous carcinoma, similar to type I endometrial carcinoma that develops after estrogen stimulation.

6. Prevention of High-Grade Serous Carcinoma {#sec6-diagnostics-10-00120}
============================================

6.1. Surgical Prevention {#sec6dot1-diagnostics-10-00120}
------------------------

Surgical risk reduction, particularly RRSO, plays an important role in the prevention of ovarian carcinoma in high-risk women. RRSO was associated with an 85% reduction in *BRCA1*-associated gynecological (ovarian, fallopian tube, or primary peritoneal) cancer risk \[[@B98-diagnostics-10-00120]\]. In that study, protection against *BRCA2*-associated gynecological cancer was suggested, but the effect did not reach statistical significance. RRSO is recommended before age 40, but ideally by age 35, for women with a *BRCA1* mutation and before age 45 for women with a *BRCA2* mutation \[[@B99-diagnostics-10-00120]\]. However, RRSO performed in premenopausal women causes endocrine symptoms and sexual symptoms associated with a decrease in estrogen levels, in addition to psychological distress. To avoid these adverse consequences of premature menopause, new preventive measures, such as bilateral salpingectomy with delayed oophorectomy, have been investigated \[[@B100-diagnostics-10-00120]\]. However, ovarian preservation may place patients at risk for ovarian cancer which develops from OSE, a lesion formed by precursor escape \[[@B39-diagnostics-10-00120]\] or from residual fimbrial tissue remaining of the ovarian surface \[[@B101-diagnostics-10-00120]\]. For average-risk women after the completion of childbearing, opportunistic salpingectomy during benign gynecological surgery, which appears to be safe and may offer some protection from ovarian cancer, is now recommended by several professional societies \[[@B102-diagnostics-10-00120]\].

6.2. Non-Surgical Prevention (Chemoprevention) {#sec6dot2-diagnostics-10-00120}
----------------------------------------------

In high-risk women, i.e., women with a *BRCA* mutation, chemoprevention may be considered \[[@B9-diagnostics-10-00120]\]. The cumulative risks for ovarian cancer by age 70 years were estimated to be 59% for *BRCA1* carriers and 17% for *BRCA2* carriers \[[@B103-diagnostics-10-00120]\], and germline *BRCA1* and *BRCA2* mutations were exclusively associated with high-grade serous histology \[[@B104-diagnostics-10-00120]\]. It appears that incessant retrograde bleeding plays a key role in the pathogenesis of HGSC; the reduction of this bleeding can reduce the HGSC risk. In women with a *BRCA* mutation, combined OC use reduces ovarian cancer risk \[[@B105-diagnostics-10-00120],[@B106-diagnostics-10-00120]\]. Recently, extended and continuous regimens of combined OC can be utilized \[[@B107-diagnostics-10-00120]\], and these regimens may be more effective than monthly OCs which are associated with monthly bleeding. Additionally, anti-inflammatory drug use during a bleeding period may reduce ovarian cancer risk \[[@B108-diagnostics-10-00120]\]. Although OC use may increase breast cancer risk slightly, the overall cancer risk, including ovarian and endometrial cancer, may still be lower in OC users \[[@B109-diagnostics-10-00120]\]. Of note, the use of progestogen-only products for hormonal contraception was not associated with ovarian cancer risk \[[@B110-diagnostics-10-00120]\], whereas progesterone could eliminate p53-defective fallopian tube cells \[[@B111-diagnostics-10-00120]\].

In menopausal women with intact uteri, continuous estrogen and progestin regimens should be given as MHT for \<5 years \[[@B112-diagnostics-10-00120]\]. In hysterectomized women with menopausal symptoms, estrogen-only should be administered for \<7 years \[[@B112-diagnostics-10-00120]\].

7. Concluding Remarks {#sec7-diagnostics-10-00120}
=====================

Ovarian cancer screening needs to detect both early fallopian tube and ovarian lesions, as FTE and OSE are cells-of-origin for HGSC of the ovary \[[@B34-diagnostics-10-00120],[@B35-diagnostics-10-00120],[@B36-diagnostics-10-00120],[@B37-diagnostics-10-00120]\]. Although ovarian cancer screening using TV-US and CA-125 is not recommended in low-risk women and high-risk women with *BRCA* mutations, for *BRCA* mutation carriers who have not yet undergone RRSO ovarian cancer screening may be considered at age 30--35 years \[[@B113-diagnostics-10-00120]\]. In moderate-risk women, screening using these methods with or without a novel method may be effective \[[@B13-diagnostics-10-00120]\]. Of patients with ovarian cancer, 14.5--24% carried germ-line mutations in cancer-associated genes \[[@B114-diagnostics-10-00120],[@B115-diagnostics-10-00120],[@B116-diagnostics-10-00120]\], including *BRCA1/2* mutations that were observed in 13.3--15.3% \[[@B117-diagnostics-10-00120],[@B118-diagnostics-10-00120],[@B119-diagnostics-10-00120]\]. Women with mutations in moderate penetrance genes, such as *RAD51C*, *RAD51D,* and *BRIP1* mutations, have a lifetime risk of 5.2--12% \[[@B9-diagnostics-10-00120],[@B120-diagnostics-10-00120]\] and may benefit from ovarian cancer screening. Older age is associated with having a carcinoma \[[@B121-diagnostics-10-00120]\], and 69% of new cases occur among women ages 55 and older \[[@B17-diagnostics-10-00120]\]. Since most ovarian cancers develop after menopause and spontaneous menopause occurs at a mean age of 51--52 years \[[@B93-diagnostics-10-00120]\], the threshold for increased risk is around age 50. Thus, postmenopausal women ≥50 years of age with a family history of ovarian cancer may receive ovarian cancer screening. Many moderate penetrance genes, as well as *BRCA1/2*, are associated with homologous recombination DNA repair defects and they are most commonly observed in HGSCs \[[@B122-diagnostics-10-00120]\], hence, effective screening methods are needed to detect precursor lesions during a window period between the development of a STIC and initiation of invasive carcinoma, 6--7 years \[[@B123-diagnostics-10-00120],[@B124-diagnostics-10-00120]\]. The fact that the incidence of ovarian carcinoma has been decreasing in recent years with the increase in OC use and the decrease in MHT use \[[@B125-diagnostics-10-00120],[@B126-diagnostics-10-00120]\] may suggest the possibility of hormonal prevention of ovarian carcinoma.

HGSC is not a single disease but a group of neoplasms that include different transcriptional subtypes and different histopathological subtypes \[[@B21-diagnostics-10-00120],[@B127-diagnostics-10-00120]\]. FTE-derived HGSC metastasizes rapidly and OSE-derived HGSC has longer latency, lower penetrance, and a worse prognosis \[[@B35-diagnostics-10-00120],[@B36-diagnostics-10-00120]\]. To better select candidates for ovarian cancer screening, further studies are needed to identify subtype-specific risk factors and genotype-phenotype correlations and to explore tumor evolution.
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diagnostics-10-00120-t001_Table 1

###### 

Detection methods for high-grade serous carcinoma of the ovary and fallopian tube.

  Theoretically Detectable Tumor Size   Detection Methods    Ref                   
  ------------------------------------- -------------------- --------------------- -----------------------------------------------------------------------------------------------------------------
  Gross adnexal mass                                         TV-US                 \[[@B2-diagnostics-10-00120],[@B13-diagnostics-10-00120]\]
  Small invasive carcinoma              Blood                CA-125 (+ TV-US)      \[[@B1-diagnostics-10-00120],[@B3-diagnostics-10-00120],[@B4-diagnostics-10-00120],[@B7-diagnostics-10-00120]\]
                                                             Tumor DNA             \[[@B42-diagnostics-10-00120]\]
                                                             DNA methylation       \[[@B43-diagnostics-10-00120]\]
                                                             Protein + Tumor DNA   \[[@B44-diagnostics-10-00120]\]
                                                             Glycoprotein          \[[@B45-diagnostics-10-00120]\]
                                                             Autoantibody          \[[@B46-diagnostics-10-00120]\]
  Intraepithelial neoplasia             Cervical mucus       Tumor DNA             \[[@B69-diagnostics-10-00120],[@B70-diagnostics-10-00120],[@B71-diagnostics-10-00120]\]
                                        Endometrial sample   Cytology              \[[@B48-diagnostics-10-00120],[@B49-diagnostics-10-00120]\]
                                        (lavage)             Tumor DNA             \[[@B72-diagnostics-10-00120]\]
                                                             Proteome              \[[@B73-diagnostics-10-00120]\]
                                        Blood                Micro RNA             \[[@B77-diagnostics-10-00120],[@B78-diagnostics-10-00120]\]
                                        Urine                Micro RNA             \[[@B75-diagnostics-10-00120]\]
                                        Exhaled breath       Volatile gas          \[[@B76-diagnostics-10-00120]\]
                                        Falloposcopy         Cytology              \[[@B74-diagnostics-10-00120]\]
                                                             Autofluorescence      \[[@B79-diagnostics-10-00120]\]
                                        Biofluid (pelvis)    Optical nanosensor    \[[@B80-diagnostics-10-00120]\]

diagnostics-10-00120-t002_Table 2

###### 

Cases of fallopian tube and ovarian cancer detected by endometrial/cervicovaginal cytology without abnormalities on imaging studies.

  No.                  Author (Year)                                      Age (Years)   Stage           CA-125 (U/mL)   CV/Em Cytology   Em Biopsy   Site                             Histologic Type
  -------------------- -------------------------------------------------- ------------- --------------- --------------- ---------------- ----------- -------------------------------- -----------------------------
  Asymptomatic cases                                                                                                                                                                  
  1                    Otsuka (2013) \[[@B49-diagnostics-10-00120]\]      58            0 ^A^           10              Pos/Pos          Neg         not specified                    unknown
  2                    Narutomi (2001) \[[@B50-diagnostics-10-00120]\]    72            Ic (TIC ^B^)    ≤35             Pos/Pos          Neg         FT (Rt)                          papillary
  3                    Safret (2004) \[[@B51-diagnostics-10-00120]\]      36            Ic (TIC ^B^)    ≤35             Pos/―            Neg         FT (Lt)                          ―
  4                    Doi (1991) \[[@B52-diagnostics-10-00120]\]         52            Ic              11              Pos/Pos          Neg         FT (Rt)                          papillary
  5                    Maeda (2010) \[[@B53-diagnostics-10-00120]\]       57            Ic              ≤35             ―/Pos            Susp        FT (Bil)                         serous
  6                    Yamakawa (1991) \[[@B54-diagnostics-10-00120]\]    54            Ic              ≤35             Pos/Pos          Neg         FT (Rt)                          papillary
  7                    Iida (1989) \[[@B55-diagnostics-10-00120]\]        40            Ic              48              Pos/Pos          Neg         FT (Lt)                          papillary medullary
  8                    Konishi (2011) \[[@B56-diagnostics-10-00120]\]     65            Ic              307             Susp/Pos         Neg         FT (Rt)                          endometrioid
  9                    Warshal (1999) \[[@B57-diagnostics-10-00120]\]     76            I ^C^           6               Pos/―            ―           FT (Lt)                          serous, G2
  10                   Kawanishi (2009) \[[@B58-diagnostics-10-00120]\]   55            IIa             ≤35             Neg/Pos          Neg         FT (Rt), Ov (Bil)                serous
  11                   Otsuka (2013) \[[@B49-diagnostics-10-00120]\]      69            IIb             42              Susp/Pos         Neg         FT (Lt), Ov (Lt)                 serous, G3
  12                   Ikarashi (1995) \[[@B59-diagnostics-10-00120]\]    57            IIb (TIC ^B^)   \<9             Pos/Pos          Neg         FT (Lt), Ov (Lt)                 papillary
  13                   Otsuka (2013) \[[@B49-diagnostics-10-00120]\]      55            IIb             47              Neg/Pos          Neg         FT (Rt), Ov (Lt)                 serous, G2
  Symptomatic cases                                                                                                                                                                   
  14                   Minato (1998) \[[@B60-diagnostics-10-00120]\]      70            0 (TIC ^B^)     ≤35             Neg/Pos          ―           FT (Lt)                          papillary
  15                   Fujimoto (1989) \[[@B61-diagnostics-10-00120]\]    75            0 (TIC ^B^)     ≤35             Pos/―            Neg         FT (Lt)                          ―
  16                   Imamura (2012) \[[@B62-diagnostics-10-00120]\]     64            Ic              10.1            Pos/Pos          Neg         FT (Rt)                          endometrioid
  17                   Iwamoto (2002) \[[@B63-diagnostics-10-00120]\]     56            Ic              14.8            Neg/Pos          ―           FT                               ―
  18                   Takeda (1991) \[[@B64-diagnostics-10-00120]\]      69            Ic              19              Neg/Pos          Neg         Ov (Rt)                          serous
  19                   Suzuki (1985) \[[@B65-diagnostics-10-00120]\]      58            I               23              Neg/Pos          Neg         FT (Lt)                          poorly-diff
  20                   Luzzatto (1996) \[[@B66-diagnostics-10-00120]\]    57            I               115             Neg/Pos          ―           FT (Lt)                          ―
  21                   Iwamoto (2002) \[[@B63-diagnostics-10-00120]\]     52            IIIa (T2bN1)    9               Neg/Pos          ―           FT, LNs                          ―
  22                   Miyao (2011) \[[@B67-diagnostics-10-00120]\]       50s           IIIa (T3N1)     84.7            Neg/Pos          ―           FT (Rt), Ov (Rt), Omentum, LNs   poorly-diff
  23                   Ohta (2009) \[[@B68-diagnostics-10-00120]\]        64            IIIb            386             Neg/Pos          Neg         FT (Rt), Extrapelvis             endometrioid G3, clear cell

All symptomatic cases presented vaginal bleeding. ^A^ In this patient, the original tumor was unable to be found. ^B^ Fallopian tube lesion is intraepithelial carcinoma. ^C^ Fallopian tube carcinoma developed after vaginal hysterectomy. CV, cervicovaginal; Em, endometrial; ―, not reported; Neg, negative; Pos, positive; Susp, suspicious; FT, fallopian tube; Ov, ovary; Bil, bilateral; Rt, right; Lt, left; LN, lymph node; TIC, tubal intraepithelial carcinoma.
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###### 

Menopausal hormone therapy and risk of serous carcinoma.

                            Estrogen Alone   Sequential Estrogen and Progestin   Continuous Estrogen and Progestin   Ref   
  ------------------------- ---------------- ----------------------------------- ----------------------------------- ----- -------------------------------------------------------------
  Ovarian cancer (serous)   ↑                ↑                                   ↑                                   →     \[[@B90-diagnostics-10-00120],[@B92-diagnostics-10-00120]\]
  Fallopian tube cancer     →                                                    ↑                                   →     \[[@B91-diagnostics-10-00120]\]
